On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.

Protein degradation–focused Neomorph nabs its third Big Pharma deal of around $1.5 billion in less than a year.

In a good-news-bad-news week for Biogen, the company will cut an undisclosed number of employees, just as a higher dose of ...

Looking for a biopharma job in New Jersey? Check out the BioSpace list of eight companies hiring life sciences professionals ...

M&As are stressful for multiple reasons, including role changes and getting laid off when staffs combine. Two talent experts ...

Turn your career aspirations into reality with this step-by-step guide to creating and implementing a strategic professional ...